Nektar Therapeutics (NKTR) Cash & Current Investments (2010 - 2026)

Nektar Therapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $568.6 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 160.07% year-over-year to $568.6 million; the TTM figure through Mar 2026 stood at $568.6 million (up 160.07% YoY), while the FY2025 annual figure was $245.8 million, down 3.71% from the prior year.
• Cash & Current Investments was $568.6 million for Q1 2026 at Nektar Therapeutics, up from $245.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $667.0 million in Q1 2022 to a low of $175.9 million in Q2 2025.
• Historically, Cash & Current Investments has averaged $377.6 million across 5 years, with a median of $303.6 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Cash & Current Investments slumped 40.68% in 2022, then soared 160.07% in 2026.
• A 5-year view of Cash & Current Investments shows it stood at $505.0 million in 2022, then slumped by 39.88% to $303.6 million in 2023, then decreased by 15.94% to $255.2 million in 2024, then decreased by 3.71% to $245.8 million in 2025, then soared by 131.37% to $568.6 million in 2026.
• The last three Cash & Current Investments figures came in at $568.6 million (Q1 2026), $245.8 million (Q4 2025), and $270.2 million (Q3 2025), per Business Quant data.